Massive Digestive Hemorrhagia Revealing a Gastro-Intestinal Stromal Tumor of the Jejunum

Yasmine Cherouaqi, Fatima zahra Belabbes, Hanane Delsa, Anass Nadi, Fedoua Rouibaa

1. Gastroenterology and Proctology, Faculty of Medicine, Mohammed VI University of Health Sciences (UMoSS) Cheikh Khalifa International University Hospital, Casablanca, MAR

Corresponding author: Yasmine Cherouaqi, cherouaqi.yasmine@gmail.com

Abstract
Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that originate from Cajal cells located in different sites of the digestive system. They may occur in the entire gastrointestinal tract. They are diagnosed on the basis of the identification of c-kit-positive cells. We report a case of a stromal tumor of the jejunum revealed by a massive digestive hemorrhagia. Surgical resection is the basis of the treatment of GISTs. Imatinib, a tyrosine kinase inhibitor, is a beneficial treatment after surgical resection of high-risk GISTs.

Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. They may occur in the entire length of the GI system, from the esophagus to the anus, and sometimes in the omentum [1]. The small intestine is the second most frequent location of GISTs after the stomach. The jejunal GISTs account for only 0.1% to 3% of all gastrointestinal tumors [2]. GISTs are diagnosed on the basis of the identification of c-KIT-positive cells [1]. In addition to surgery, they can be treated by imatinib which inhibits the KIT kinase activity. The treatment of advanced GIST is evolving rapidly with the development of new molecular compounds such as avapritinib and ripretinib [3]. In this work, we present an unusual case of a jejunal GIST revealed by a massive hemorrhagia.

Case Presentation
A 40-year-old male with no specific pathological history presented high volume melena. He had several episodes of melena for the last six years, periumbilical pain, vomiting, a not-tolerated anemic syndrome, a weight loss of nine kilograms, and asthenia. He didn’t have hematemesis, hematochezia, transit disorder, or anorexia. The physical examination at the admission found a tachycardia patient at 110 beats per minute, a normal blood pressure, oxygen saturation of 96%, and discolored conjunctiva. The abdominal exam was normal, as well as the rest of the clinical examination. At the biology report, there was normochromic normocytic anemia at 8.9 g/dL. The rest of the biological examination was normal. After transfusion and hemodynamic stabilization, the patient had an oeso-gastroduodenal fibroscopy. It showed erythematous gastritis. The ileocolonoscopy showed melena without any endoscopic lesion. An entero-computed tomography (CT) revealed a parietal tumor mass of the third jejunal loop, with endoluminal development and irregular outlines, measuring 34x30 mm, extended over 5 cm, with infiltration of the adjacent fat. This mass was in contact with the adjacent jejunal loop without separation of the border (Figure 1). The thoracic CT showed a pleural nodule with a non-specific appearance.
Surgical intervention was indicated for therapeutic purpose. The exploration of the entire abdominal cavity didn’t find any metastases or lymph node extension (Figure 2). The patient had a segmental enterectomy of 15 cm of the jejunal GIST with an end-to-end jejunal anastomosis (Figure 3). There were no complications in the postoperative period. The histopathologic exam showed a gastrointestinal stromal tumor with a low risk of recurrence. The mitotic index was less than five. The patient started imatinib with good tolerance. The abdominal CT after six months, one year, and two years of treatment were normal.
FIGURE 2: The appearance of the jejunal GIST during surgery

GIST - gastrointestinal stromal tumor
Discussion

Gastrointestinal stromal tumors are specific tumors of the gastrointestinal tract. They originate from Cajal cells located in different sites of the digestive tract [4]. They are a rare group of digestive tumors that make up about one percent of all gastrointestinal cancers [5]. In the stomach, the most common site of GIST, benign tumors outnumber the malignant ones by a wide margin, whereas most esophageal and colonic GISTs are malignant. In the early literature, these tumors were classified as leiomyomas, cellular leiomyomas, leiomyoblastomas, and leiomyosarcomas [6]. They are defined as KIT-positive (CD17, stem cell factor receptor) mesenchymal spindle cell neoplasm or primary epithelioid neoplasm in the gastrointestinal tract, omentum, and mesentery [6]. GISTs have a peak incidence between the 5th and 6th decades, although it may occur at any age [7]. There is no predilection for both sexes [7]. Only 70% of patients with a GIST are symptomatic. In 20% of cases, they are asymptomatic, and tumors are detected incidentally. The symptoms are not specific to the disease [9-10]. The clinical presentation of patients with GISTs depends on the anatomic location of the primary lesion. The most frequent symptoms are abdominal pain (67.4%), abdominal mass (31.2%), bowel obstruction (24.1%), hematochezia (21.3%), and fever (14.2%). They can be responsible for chronic gastrointestinal bleeding, causing hematemesis, melena, or anemia. In rare cases, acute massive bleeding can occur [11]. Wild-type GIST is frequently associated with inherited syndromes such as carney’s triad and neurofibromatosis type 1. They often affect the pediatric population and young adults [12]. The preoperative diagnosis can be difficult. It is often confirmed during surgery. Endoscopic and imaging examinations are often essential to establish the preoperative diagnosis. The study of the small intestine requires the use of entero-magnetic resonance imaging (MRI). It is an alternative to entero-CT. The GISTs most often have the appearance of an exophytic mass with regular contours. They can also take on the appearance of a small wall nodule as in CT. In T1 weighting, the signal from GISTs is generally intermediate, sometimes with hypersignals indicating hemorrhage [13]. The endoscopic appearance of GISTs is not very specific. It is generally an aspect of a regular nodule, submucosal in appearance because it is covered with normal mucosa. Endoscopic biopsies are most often negative. Ultrasound endoscopy is the best examination to characterize eso-gastro-duodenal or rectal submucosal lesions. GISTs appear as inhomogeneous hypoechoic lesions [14]. Endoscopic, endosonographic, or imaging features are suggestive but not diagnostic of GIST. In practice, only the anatomopathological aspect, and especially the search for the expression of c-KIT, will allow the diagnosis to be confirmed with certainty. Histologically, GISTs are of three types: spindle cell type (70%), epithelial type (20%), and mixed type (10%). The immunohistochemical study shows the expression of KIT by tumor cells in 95% of cases [15]. The National Institutes of Health (NIH) and Armed Forces Institute of Pathology (AFIP) risk classification criteria are commonly used to predict the prognosis of GISTs. The aggressiveness of GISTs
depends on size, mitotic index, and location [16-17]. Metastases in GISTs have been reported in 50% of patients. The vast majority of metastases from GISTs, at presentation or at disease recurrence, are intra-abdominal, with metastases to the liver, omentum, or peritoneal cavity [18]. Treatment of GISTs depends on risk stratification. Surgery is the treatment of choice, but various endoscopic resection modalities are being more and more tried. Surgery is the treatment of choice for symptomatic localized GIST [18-19]. Endoscopic therapy is mainly used for the treatment of GISTs of the upper digestive tract in patients without recurrence or metastasis [19]. The tyrosine kinase inhibitor (TKI), imatinib, radically changed the natural history of KIT-induced GISTs; approximately 90% of GISTs have an activating mutation of the KIT or PDGFR alpha oncogene known to confer sensitivity to imatinib [20]. Approximately 80% of patients with metastatic GIST show at least some clinical response to imatinib, a targeted small molecule KIT inhibitor [3].

Conclusions
GISTs are rare tumors in our context. Testing for KIT and PDGFRα gene mutations is recommended, with exception of GISTs of very low risk of recurrence. Imatinib is the standard adjuvant treatment after R0 resection of GIST of high risk of recurrence and the first-line treatment of advanced GIST. This case presents an unusual presentation of a jejunal GIST and its management. More researches are necessary to better clarify and update their management.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Miettinen M, Lasota J: Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol. J. Pathol. 2003, 54:3-24.
2. Melo C, Canhoto C, Manata F, Bernardes A: Surgical treatment of giant gist with acute gastrointestinal bleeding: case report. Int J Surg Case Rep. 2018, 53:554-7. 10.1016/j.ijscar.2018.11.021
3. Farag S, Smith MJ, Fotiadis N, Constantioudou A, Jones RL: Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. Curr Treat Options Oncol. 2020, 21:55. 10.1007/s11864-020-00754-8
4. Caliskan C, MD, Makay O, and al.: Massive gastrointestinal bleeding caused by stromal tumour of the jejunum. Canadian Journal of Surgery. 2009, 52:E185-7.
5. Margia R, Loriga A, Vadilonga F and al.: Lower gastrointestinal bleeding due to jejunal gastrointestinal stromal tumour (GIST): case report. Dig Liver Dis. 2008, 40:72. 10.1016/s1590-8658(08)0184-x
6. Appelman HD: Mesenchymal tumors of the gut: historical perspectives, new approaches, new results, and does it make any difference?: Gastrointestinal pathology. 1990, 51:220-46.
7. Sharaglia M, Businello G, Bellan E, Fassan M, Dei Tos AP: Mesenchymal tumours of the gastrointestinal tract. Pathologica. 2021, 113:250-51. 10.5207/1459-951X-309
8. Miettinen M, Lasota J: Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001, 458:1-12. 10.1007/s11864-000-0338
9. Govindaraj S, Dias BH, Gautam SL: A sporadic small jejunal GIST presenting with acute lower gastrointestinal hemorrhage: a review of the literature and management guidelines. Indian J Surg. 2015, 77:145-6. 10.1007/s12262-015-1208-9
10. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC: Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005, 41:2868-72. 10.1016/j.ejca.2005.09.009
11. Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF: Surgically treated primary malignant tumor of small bowel: a clinical analysis. World J Gastroenterol. 2010, 16:1527-32. 10.3748/wjg.v16.i12.1527
12. Djerouni M, Dumont SN: Wild-type gastrointestinal stromal tumors. Bull Cancer. 2020, 107:499-505. 10.1016/j.bulcan.2019.12.007
13. Benjamins B, Soyer P, Roudiak M and al: Imaging of gastrointestinal stromal tumors. Journal de Radiologie. 2009, 90:469-80. 10.1016/j.jradic.2008.05.006
14. Landi B: Gastrointestinal stromal tumors (GIST): diagnosis and treatment (excluding endoscopic treatments). POSTU. 2019.
15. Demetri GD, von Mehren M, Antonescu CR, et al.: NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010, 8 Suppl 2:S1-41; quiz S42-4. 10.6004/jnccn.2010.0116
16. Joensuu H: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008, 39:1411-9. 10.1016/j.humpath.2008.06.025
17. Yang ML, Wang JC, Zou WB, Yao DK: Clinicopathological characteristics and prognostic factors of gastrointestinal stromal tumors in Chinese patients. Oncol Lett. 2018, 16:4905-14. 10.3892/ol.2018.9520
18. Fülöp E, Marcu S, Milutil D, Borda A: Gastrointestinal stromal tumors: review on morphology, diagnosis
and management. Romanian Journal of Morphology and Embryology. 2009, 50:319-26.
19. Marcella C, Sarwar S, Ye H, Shi RH: Efficacy and safety of endoscopic treatment for gastrointestinal stromal tumors in the upper gastrointestinal tract. Clin Endosc. 2020, 53:458-65. 10.5946/ce.2019.121
20. Hornick JL, Fletcher CD: The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol. 2007, 38:679-87. 10.1016/j.humpath.2007.03.001